Biomedizinische Forschungsgesellschaft m.b.H.

Forschungsschwerpunkte: designs and produces microbial antigens by recombinant technology; individual antigens are well-defined and thoroughly investigated for their biological properties. The vaccines will be adjuvanted with conventional adjuvants, as well as with a pattented nano adjuvant